Aarhus, Denmark (April 20) – CERCARE Perfusion is implemented at Aarhus University Hospital (AUH), Denmark, to be used in a pilot project to assess treatment response in brain tumors. AUH is one of the 5 national super hospitals in Denmark and is awarded Denmark’s Best Hospital 13 times in a row by the independent specialist newspaper of healthcare sector news ”Dagens Medicin”(1).

There are approximately 1,500 new cases of a primary brain tumor in Denmark each year, and about 15,000 people live with the diagnosis of primary brain tumor, including both patients in active treatment or follow-up regime or people in full recovery(2). After surgery, management of oncology patients for radiotherapy requires regular imaging follow-up to gauge the success of the treatment as well as the timely discovery of new tumor activity. Department of Radiology (Section of Neuroradiology) at AUH has decided to include perfusion imaging in follow-up which is technically difficult and requires a robust solution to ensure smooth clinical workflow.

The choice for a pilot project fell on CERCARE Perfusion provided by Cercare Medical, a spin-out from Aarhus University with a long history of collaboration in the field of acute stroke imaging and now extending their work to tumor imaging.

CERCARE Perfusion is a fully automated perfusion imaging solution with smart AIF selection powered by artificial intelligence. The technology is grounded in more than 15 years of research in perfusion imaging and is based on the unique approach that accounts for capillary function and integrity allowing to generate both traditional and unique parametric maps that reflect brain tissue oxygenation.

“We are very excited to have CERCARE Perfusion installed at AUH. This deepens our long-standing collaboration bringing innovation from early research to robust clinical usage. It was our goal to bring our research to life and make it available for healthcare professionals in clinical settings. We believe that our approach to perfusion imaging can have a significant influence on how patients are diagnosed and treated.  As we continue broadening our installations across Europe and the USA, our continuous collaboration with AUH is very important to us and we look forward to having more projects together”, says Kim Beuschau Mouridsen, founder and CEO of Cercare Medical.

Learn more about CERCARE Perfusion and how it is used to assess oncology in brain here.

About Aarhus University Hospital

Aarhus University Hospital develops and provides highly specialized treatment, research, and education at the international level.

AUH has an eventful history. In 2004 the two old somatic hospitals in the city of Aarhus, Aarhus Kommunehospital and Aarhus Amtssygehus, merged to form Aarhus University Hospital, Aarhus Sygehus. In 2011 Aarhus University Hospital, Aarhus Sygehus, and Aarhus University Hospital, Skejby, merged to form a united Aarhus University Hospital (AUH). A relocation of clinical and research departments from the former Aarhus Sygehus to the united AUH took place from 2014 to 2019 with the building of the new university hospital in addition to the existing hospital in Skejby.

The new Aarhus University Hospital is among the largest in Europe and houses 41 clinical departments and employs over 10,000 people. The hospital area covers 500,000 m2.

Learn more about AUH here https://www.en.auh.dk/



Tatiana Karpenko
Marketing Manager

Cercare Medical
Phone: +45 52635778